BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development

What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities 

Plus: Delay in Senate for drug pricing votes plus updates from Ten63, FDA, Immatics, Travere, Ascletis and more   

Megaround for cross-border cell therapy company follows privatization led by Tony Liu

The latest cut of Arcellx’s Phase I data for its BCMA-directed CAR T cell therapy maintains the candidate’s position as one of the top-performing CAR Ts against the target.  In an

It’s no longer only MNCs. CEOs from domestic biotechs, academia and investment communities a growing source of China CEOs

Suzhou company shines in first day of trading after raising more than $200M

SomaLogic tops off recent series AProteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total

Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point

$383M deal set against backdrop of White House, Senate push to tighten auditing rules